Rapid Serological Tests and Immunity Policies: Addressing Ethical Implications for Healthcare Providers and the Healthcare System as a Priority

  • Marie-Alexia Masella Programme de bioéthique, École de santé publique de l'Université de Montréal, Montréal, Canada https://orcid.org/0000-0001-6979-4943
  • Hortense Gallois Center of Genomics and Policy, McGill University, Montréal, Canada https://orcid.org/0000-0003-1876-2209
  • Jean-Christophe Bélisle-Pipon Petrie-Flom Center, Harvard Law School, Cambridge, USA; Health Law Institute, Dalhousie University, Halifax; Centre de recherche en éthique, Montréal, Canada https://orcid.org/0000-0002-8965-8153
Keywords: public health, healthcare providers, serological tests, COVID-19, ethics

Abstract

Healthcare providers (HCP) have been central actors in containing the COVID-19 pandemic. Although potentially very beneficial, the implementation of large-scale rapid serological tests raises ethical dilemmas and affects HCPs’ capacity to work in optimal conditions. In this regard, we call for attention to address specific and urgent ethical issues distinctively affecting HCPs following the availability and possible mandatory use of rapid serological tests for COVID-19.

Published
2020-11-16
How to Cite
[1]
Masella M-A, Gallois H, Bélisle-Pipon J-C. Rapid Serological Tests and Immunity Policies: Addressing Ethical Implications for Healthcare Providers and the Healthcare System as a Priority. Can. J. Bioeth. 2020;3:177-9. https://doi.org/10.7202/1073796ar.
Section
Perspectives